根据ELN 2022标准,与中危AML患者相比,低危AML患者的生存期得到了显著改善(HR 0.44;95%CI,0.30-0.65;P<0.001),而不良风险AML患者的生存期显著较差(HR 1.62;95%CI:1.20-2.20;P=0.002);根据ELN 2017标准,与中危AML患者相比,低危AML患者的...
According to the current European Leukemia Network guidelines (ELN 2022) for diagnosis and treatment of acute myeloid leukemia (AML) the prognostic risk stratification is based on molecular and cytogenetic characterization. Due to the small number of prospective Minimal Residual Disease (MRD) driven ...